The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations

As China has become the world's second-largest economy and the largest developing country, its economy and market have assumed a prominent position in the Asia-Pacific region. The pharmaceutical industry is an important part of China's national economy, with continuous strong demand, need, and capability for innovation. The industry continues to experience high levels of growth. With China's increasing emphasis on the pharmaceutical industry, and the gradual improvement of healthcare policies, momentum supporting the development of China’s pharmaceutical market continues to accelerate. As the sector’s market structure continues to become more optimized, the Chinese pharmaceutical market as a whole has shown a stable and positive pattern, and its current advantages and future potential are also attracting increasing numbers of overseas companies to do business in China.

This article will analyze the Chinese pharmaceutical market from four aspects: a market overview, the regulatory and reimbursement environment, foreign pharmaceutical companies’ strategies in China, and the current state of innovation adoption.

Open PDF

Return to Insights Center

Related Insights


New Medicines, Novel Insights: Advancing rare disease drug development

May 22, 2023


Near-term strategies for biotech drug developers facing shifting healthcare dynamics

Feb 14, 2024


New Medicines, Novel Insights: Accelerating development of cell and gene therapies

May 22, 2023


Are you using real-world evidence?

Feb 1, 2023


New FDA Guidance Addresses the Need for Data-Generation Strategies Across the Drug Development Lifecycle

May 10, 2022


Maintaining Data Integrity for Quality and Compliance – Essential Despite Pandemic Disruptions

May 16, 2022


RBQM Podcast Series | Episode 3: Staying within the Guardrails: How to Push the Boundaries in a Highly Regulated Industry

Jun 16, 2022


8 things you need to know about eCTDs in China

Jul 1, 2022


Preparing for the New Era of Hybrid Regulatory Inspections

Jul 11, 2022


EU Orphan Drug Designation – overcoming regulatory challenges

Jul 20, 2022


China's Market Approval Policy and Medical Insurance Payment System for Rare Disease

Jul 21, 2022


Preparing for a new era in European Market Access

Jul 22, 2022